fda warning letter glp-1 solution september 2025 issued 30 letters to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's crackdown on misleading FDA Decisions Expected: October 2025
Description
Available in-office or via telehealth
Disclosure: I hold a bullish position in Altimmune (ALT) through call options expiring January 2027 a leveraged, directional position that profits if the stock rises
Novo Nordisk, Hims & Hers, Eli Lilly, and Ro are all marketing in and around Super Bowl 60.
#retatrutide is a novel triple agonist peptide at the glucagon receptor, GIP receptor, and GLP-1 receptor
Metabolic Engineering activates the same pathway naturally without the side effects.
Supports Weight Management: By improving gut health and promoting a healthy metabolism, Akkermansia assists with natural weight regulation
